NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveMeningeal Chronic Myelogenous LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRelapsing Chronic Myelogenous LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00316953
- Locations
- πΊπΈ
Children's Oncology Group, Arcadia, California, United States
Stem Cell Collection
- Conditions
- Stem Cells
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 429
- Registration Number
- NCT00316069
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAlkylating Agent-Related Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 197
- Registration Number
- NCT00313586
- Locations
- πΊπΈ
Clements University Hospital, Dallas, Texas, United States
πΊπΈUnion Hospital of Cecil County, Elkton, Maryland, United States
πΊπΈHematology and Oncology Associates, Chicago, Illinois, United States
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
- Conditions
- Neurofibromatosis Type 1Neurofibroma
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00314119
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Oxaliplatin and Topotecan in Advance Ovarian Cancer
- Conditions
- Recurrent Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-11-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00313612
- Locations
- πΊπΈ
NYU Cancer Institute, New York, New York, United States
πΊπΈMontefiore Medical Center, Bronx, New York, United States
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- Biological: Melanoma Reactive TILBiological: IL-2Radiation: 1200 total body irradiation (TBI)
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00314106
- Locations
- πΊπΈ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Thyroid and Fat Tissue Metabolism
- Conditions
- Healthy Volunteers
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 41
- Registration Number
- NCT00312715
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Conditions
- Breast AdenocarcinomaStage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIB Breast Cancer AJCC v7Hormone Receptor Positive
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentRadiation: Radiation Therapy
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10273
- Registration Number
- NCT00310180
- Locations
- π΅π·
San Juan City Hospital, San Juan, Puerto Rico
πΊπΈKaiser Permanente-Franklin, Denver, Colorado, United States
πΊπΈNortheast Alabama Regional Medical Center, Anniston, Alabama, United States
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00310089
- Locations
- πΊπΈ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
πΊπΈCancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00310024
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States